Wachtell, Skadden Guide MorphoSys' $1.7B Cancer Co. Buy

By Emma Whitford (June 2, 2021, 6:13 PM EDT) -- Cancer and autoimmune disease-focused MorphoSys AG announced Wednesday that it plans to buy cancer research company Constellation Pharmaceuticals in a $1.7 billion deal guided by Skadden and Wachtell Lipton.

A MorphoSys subsidiary will pay $34 per outstanding Constellation share for an equity value of $1.7 billion, the company said in a statement. To fund the deal, MorphoSys plans to enter into an agreement with pharmaceutical licensing company Royalty Pharma, in which Royalty Pharma will pay MorphoSys an initial $1.425 billion in exchange for certain royalties.

The deal is expected to close in the third quarter of 2021, pending approvals. Skadden Arps...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!